Amdokitug (Yisaituo) vs Gumokimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-17A · full Psoriasis pipeline

Amdokitug (Yisaituo)

Marketed by Sunshine Guojian Pharmaceutical and partners

Phase 3 in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Gumokimab

Marketed by Akeso

Phase 3 in Psoriasismonoclonal antibody
Partial signal

NCT06066125 · Phase 3 · completed

The trial was properly randomized, quadruple-blinded, and placebo-controlled with over 350 participants and used hard, regulator-accepted clinical endpoints (PASI75 and sPGA 0/1). However, the only externally available result reports the gumokimab arm's response rate without the placebo arm's rate or any statistical test, so it isn't possible to confirm the pre-specified comparison was statistically significant, which keeps this well-designed trial at a moderate grade rather than strong.

Result from the sponsor's press release or a wire copy of it; no peer-reviewed publication or posted registry results were found.

Reported efficacy

The percentage of subjects who achieved at least 75% reduction in psoriasis area and severity index(PASI) score from baseline (PASI 75) and the percentage of subjects who achieved static physician global assessment(sPGA) 0/1 at week 12.: PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7% (unclear)

Result source: NCT06066125

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAmdokitug (Yisaituo)Gumokimab
PASI 75—Not posted · NCT05536726—Not posted · NCT06066125
PASI 90—Not posted · NCT05536726—Not posted · NCT06066125
PASI 100—Not posted · NCT05536726—Not posted · NCT06066125
sPGA 0/1—Not posted · NCT05536726—Not posted · NCT06066125
DLQI, change—Not posted · NCT05536726—Not posted · NCT06066125

PASI 75

Amdokitug (Yisaituo)
—Not posted · NCT05536726
Gumokimab
—Not posted · NCT06066125

PASI 90

Amdokitug (Yisaituo)
—Not posted · NCT05536726
Gumokimab
—Not posted · NCT06066125

PASI 100

Amdokitug (Yisaituo)
—Not posted · NCT05536726
Gumokimab
—Not posted · NCT06066125

sPGA 0/1

Amdokitug (Yisaituo)
—Not posted · NCT05536726
Gumokimab
—Not posted · NCT06066125

DLQI, change

Amdokitug (Yisaituo)
—Not posted · NCT05536726
Gumokimab
—Not posted · NCT06066125
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Amdokitug (Yisaituo): no structured comparison results are available for Psoriasis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Gumokimab
PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7% NCT06066125 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amdokitug (Yisaituo)'s landscape · Gumokimab's landscape